Actos is a drug frequently prescribed for those with Type 2 diabetes. Takeda, a Japanese pharmaceutical company, began manufacturing Actos in 1999.
Actos (pioglitazone) is a prescription drug used in the treatment of Type 2 Diabetes. Approved in 1999, the drug has been on the market for over thirteen years, and at one time was considered a safe alternative to the drug Avandia (which was targeted for contributing to adverse cardiovascular events in users).
The drug Actos, also known as pioglitazone is marketed by Takeda Pharmaceuticals and Eli Lilly for the treatment of Type 2 diabetes. The drug was approved in 1999, and although the manufacturer touts it as a miracle drug which has reduced the number of diabetes cases by as much as 70%, the side effects may far outweigh the benefits. A study done in 2003 by the Mayo Clinic definitively linked Actos to swelling in the feet, lung fluid retention, shortness of breath and congestive heart failure.